1525 O'Brien Drive
About GRAIL, LLC
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.
CEO: Bob Ragusa
91 articles with GRAIL, LLC
GRAIL Announces Appointment of Key Executives as Company Makes Continued Progress in Development of Early Detection Products
George Golumbeski Appointed as President
Hebrew University Researchers to Collaborate With GRAIL
Strategic partnership will focus on generating methylation data as part of ongoing research for early cancer detection
With the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting ongoing, there are hundreds of newsworthy stories. Here is a few of our top picks so far.
GRAIL Announces Data on Detection of Early-Stage Lung Cancers
GRAIL, Inc. announced new data from the Circulating Cell-free Genome Atlas (CCGA) study.
Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals
5/29/2018It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs.
Grail Raises $300 Million from China Investors for Early Cancer Diagnostics
Grail announced a $300 million C financing. Since early 2016, Grail has raised over $1.5 billion.
With a new chief executive officer on board, GRAIL, Inc. has secured a whopping $300 million in an oversubscribed Series C financing round led by multiple Chinese investment groups.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
GRAIL Poaches New CEO From Roche, Genentech
12/14/2017Four months after Jeff Huber stepped down as CEO of GRAIL, the company has tapped his replacement.
Vikram Bajaj joined Grail only a year ago.
Former Google Exec Steps Down as GRAIL CEO
Scientists Move Closer To Detecting Cancer Long Before Any Symptoms Appear, GRAIL Reveals
Bay Area GRAIL's Billion Gamble on the Perfect Cancer Test
GRAIL Announces Data From Early Research Analyzing Its High-Intensity Sequencing Approach
Cancer Screening Tie-up: Hong Kong's Cirina Merges With GRAIL, An Illumina Spin-Out
Bay Area's GRAIL Goes Global, Merges With Hong Kong's Cirina to Focus on Cancer Detection
GRAIL Announces Board Of Directors Appointments
GRAIL Initiates The STRIVE Study To Advance Development Of Blood Tests To Detect Cancer Early
A Closer Look at GRAIL, Illumina's Billion-Dollar Bay Area Diagnostics Startup
What Illumina's And Bristol-Myers Squibb's Latest GRAIL Moves Mean For Investors